Cyclerion Therapeutics, Inc. (KRSA) vs Intellia Therapeutics, Inc. (NTLA)
Cyclerion Therapeutics, Inc. and Intellia Therapeutics, Inc. are both Biotechnology companies. Cyclerion Therapeutics, Inc. and Intellia Therapeutics, Inc. are of similar size ($1.7B and $1.7B). Cyclerion Therapeutics, Inc. grew revenue faster over the last twelve months: 30.8% against 12.6%. Cyclerion Therapeutics, Inc. has the higher net margin (0.00% vs −672.2%) and the lower return on invested capital (−115.4% vs −91.3%). Across the 16 metrics below, Intellia Therapeutics, Inc. leads on 9 and Cyclerion Therapeutics, Inc. on 7.
Valuation
Profitability
| Metric | KRSA | NTLA | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | (711.66%) | 0.00% |
| Net margin | 0.00% | (672.16%) | 0.00% |
| Free cash flow margin | 0.00% | (585.82%) | 0.00% |
| Return on equity | (98.22%) | (55.44%) | (57.72%) |
| Return on assets | (82.29%) | (45.55%) | (49.22%) |
| Return on invested capital | (115.40%) | (91.28%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack